Study published in Nature Cell Biology shows how vitamin B2 helps cancer cells escape ferroptosis and points to roseoflavin as a therapeutic target.
According to ScienceDaily, researchers from the Rudolf Virchow Centre, Julius-Maximilians-Universität Würzburg, Germany, published on March 13, 2026, in Nature Cell Biology, a discovery that changes how science views the relationship between vitamin B2, cancer cells, and ferroptosis. The study revealed that riboflavin, the technical name for vitamin B2, plays a crucial role in protecting tumor cells against a specific form of programmed cell death.
The research was led by Vera Skafar, a doctoral student in the group of Professor José Pedro Friedmann Angeli. According to her, vitamin B2 helps cancer cells resist ferroptosis, a natural mechanism used by the body to eliminate cells with severe oxidative damage.
The central point of the study is the protein FSP1, Ferroptosis Suppressor Protein 1, identified as a decisive link in this defense system. In healthy cells, the mechanism is useful; in cancer cells, however, it can be exploited by the tumor to escape natural destruction.
ARTICLE CONTINUES BELOW
See also
Inside the pressure cooker, an experiment shows how steam increases the temperature, speeds up the cooking of beans, and also explains why a clogged valve can turn a common utensil into a domestic hazard.
Without air conditioning, without refrigerant gas, and using only pipes buried in the backyard, a man builds a geothermal system inspired by the “Canadian well” to cool the rooms of the house by taking advantage of the stable underground temperature and eliminates fans on the hottest nights.
Brazil aims to become a military power with more than 2,100 armored vehicles by 2040, 120 mm cannons capable of hitting targets at 5 km, amphibious vehicles at 110 km/h, and a new billion-dollar fleet for the Brazilian Army ready to modernize ground combat.
Plastic destined for landfills is turned into gasoline, diesel, and kerosene in Mexico, but Petgas technology sparks debate: real recycling or a cleaner way to burn waste while plastic pollution grows worldwide at an urgent global scale.
Vitamin B2 helps cancer cells escape ferroptosis, reveals study published in Nature Cell Biology
The discovery does not mean that vitamin B2 causes cancer, but shows that tumor cells can use riboflavin as metabolic support to survive. The vitamin participates in normal body processes, but in tumors, it can fuel a protective route against ferroptosis.
Ferroptosis is a form of programmed cell death based on oxidative damage to cell membranes. When this damage surpasses the cell’s antioxidant defenses, the membrane progressively degrades and the cell dies.
The study showed that cancer cells can reinforce this protective shield with the help of vitamin B2. This detail is relevant because many aggressive tumors rely precisely on strong antioxidant systems to resist cell death.
What is ferroptosis and why this mechanism can help the body destroy tumors
Programmed cell death is a process used by the body to eliminate damaged, infected, or potentially dangerous cells. The most well-known form is apoptosis, the target of many conventional cancer treatments.
Ferroptosis follows another path. It occurs when reactions involving iron and lipids cause lipid peroxidation, damaging cell membranes until the cell can no longer survive.
This mechanism has sparked interest because it can target tumors that have developed resistance to apoptosis. Instead of relying solely on the traditional response to chemotherapeutics, ferroptosis opens an alternative route to kill resistant cancer cells.
FSP1 protein acts as a shield against ferroptosis and can be exploited by cancer
The FSP1 protein was identified as a central piece of the mechanism described by Würzburg researchers. It exists in healthy cells to prevent accidental cell death caused by oxidative damage.
In normal cells, this function is important. It prevents healthy tissues from undergoing unnecessary ferroptosis, protecting the body against undue damage.
The problem is that cancer cells can exploit the same protein to survive. By using FSP1 as a shield, the tumor reduces its vulnerability to one of the natural mechanisms of cell elimination.
Riboflavin supports FSP1 activity and strengthens the defense of tumor cells
Vitamin B2 enters this process because it is converted by metabolism into cofactors that help sustain FSP1 activity. In this way, riboflavin indirectly participates in protection against ferroptosis.
When researchers created vitamin B2-deficient cancer cells through genomic editing, these cells became much more sensitive to ferroptosis. Without sufficient riboflavin, the defense system lost strength.
The result was direct: by reducing the metabolic support of vitamin B2, scientists were able to make tumor cells more vulnerable to programmed cell death. This is the point that turns the discovery into a possible therapeutic path.
Roseoflavin, bacterial compound, can deactivate the protective shield of cancer cells
The most promising part of the study appears in roseoflavin, a compound naturally produced by bacteria, especially Streptomyces davawensis. The molecule is structurally similar to riboflavin, which allows it to enter the cell through similar pathways.
Once inside the cell, roseoflavin binds to the FSP1 protein and interferes with its protective function. The compound prevents the protein from fulfilling its normal role of blocking ferroptosis in cancer cells.
In tests with cell models, this blockade reduced tumor protection. Without functional FSP1, cancer cells became more exposed to ferroptosis, paving the way for a therapeutic strategy based on turning off the tumor’s defense.
Discovery does not mean that vitamin B2 causes cancer or should be avoided in the diet
The correct interpretation of the study is essential. The research did not demonstrate that consuming vitamin B2 causes cancer, increases tumor risk, or should be avoided by healthy people.
Riboflavin is an essential vitamin that the human body does not produce in sufficient quantity on its own. It needs to come from food, through sources like milk, eggs, meats, spinach, mushrooms, and enriched grains.
The finding refers to cells that have already become cancerous. Vitamin B2 is not presented as a cause of cancer, but as a metabolic resource that some tumors may use to protect themselves from ferroptosis.
The therapeutic implication of the study is not to reduce vitamin B2 from the diet. This measure could harm healthy cells, as riboflavin participates in important metabolic functions in the body.
The real target is to selectively block the vitamin B2 pathway within tumor cells. Roseoflavin appears as a candidate precisely because it can interfere with the system that supports FSP1.
The ideal strategy would be to target the tumor without affecting the normal metabolism of healthy cells. This challenge of specificity is one of the main steps that researchers still need to overcome before any clinical application.
Ferroptosis has become a promising target against tumors resistant to conventional treatments
The field of ferroptosis is relatively new in biomedicine. The mechanism was described in detail only in 2012, and the first studies on its specific induction in tumors gained momentum between 2014 and 2016.
Interest grew because many cancers learn to resist treatments based on apoptosis. When this happens, tumors can escape traditional therapies and continue growing even under drug pressure.
Ferroptosis offers a different route. By exploiting oxidative vulnerabilities of cancer cells, researchers seek new ways to attack tumors that no longer respond well to classical cell death mechanisms.
Study from the University of Würzburg connects vitamin B2 to tumor resistance for the first time
The Würzburg study is important because it directly connects vitamin B2 metabolism to the resistance of cancer cells against ferroptosis. This link had not yet been described with this level of clarity.
The research was funded by the priority program Ferroptosis: from Molecular Basics to Clinical Applications, from the German Research Foundation, and by the DeciFerr project, coordinated by Professor Friedmann Angeli and supported by the European Research Council.
This funding shows that ferroptosis is already treated as a strategic field for future clinical applications. The discovery of the relationship between riboflavin, FSP1, and roseoflavin adds a new possible route for anticancer therapies.
Next challenge is to deliver roseoflavin to the tumor without affecting healthy cells
Despite the potential, the research is still at an experimental stage. The results came from cell models, and it will still be necessary to test safety, efficacy, selective delivery, and effects in living organisms.
The central challenge is to develop ways to deliver roseoflavin, or similar compounds, specifically to tumor cells. Since vitamin B2 is also essential for healthy cells, any intervention needs to avoid broad side effects.
The discovery is strong because it reveals a new mechanism and a possible vulnerability. But it is not yet a treatment available for patients, rather a promising scientific route that needs to go through new phases of validation.
Vitamin B2, FSP1, and roseoflavin open a new front in cancer research
The study published in Nature Cell Biology shows how an essential nutrient can have a dual role in the body. In healthy cells, riboflavin supports necessary functions; in cancer cells, it can strengthen a defense against ferroptosis.
The identification of FSP1 as a central link and roseoflavin as a possible blocker of the tumor shield creates a new therapeutic hypothesis. Instead of indiscriminately attacking the cells, the strategy seeks to deactivate the protection that prevents the tumor from dying through a natural process.
The advancement does not authorize hasty conclusions about diet nor does it replace existing treatments. But it reveals an important direction: understanding how cancer uses the body’s normal mechanisms against the organism itself may be the path to more precise and less aggressive therapies in the future.